CG Oncology (CGON) Change in Account Payables (2023 - 2026)
CG Oncology posted quarterly Change in Account Payables of $2.5 million for Q1 2026, up 1078.5% year-on-year from $214000.0 in Q1 2025, and up 172.49% on a QoQ basis from -$3.5 million in Q4 2025.
CG Oncology (CGON) has 4 years of Change in Account Payables data on file, last reported at $2.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 1078.5% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $664000.0 (down 67.95% YoY), and the FY2025 full-year result was -$1.6 million, down 150.2% from the prior year.
- Change in Account Payables for Q1 2026 stood at $2.5 million, up from -$3.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.5 million in Q1 2026 and bottomed at -$3.5 million in Q4 2025.
- The 4-year median for Change in Account Payables is $394000.0 (2025), against an average of $474230.8.
- Peak annual rise in Change in Account Payables reached 15844.44% in 2024, while the deepest fall reached 442.86% in 2024.
- A 4-year view of Change in Account Payables shows it stood at $1.4 million in 2023, then soared by 76.63% to $2.4 million in 2024, then slumped by 242.52% to -$3.5 million in 2025, then surged by 172.49% to $2.5 million in 2026.
- The last three Change in Account Payables figures came in at $2.5 million (Q1 2026), -$3.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.52 Mn |
| Mar 31, 2026 | 2.52 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 394,000.00 |
| Jun 30, 2025 | 394,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -415,000.00 |
| Sep 30, 2024 | -415,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 590,000.00 |
| Sep 30, 2023 | 590,000.00 |
| Jun 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 49,000.00 |
| Mar 31, 2023 | -9,000.00 |
| Mar 31, 2023 | -9,000.00 |